Psychiatric Nurse Practitioner Intake FAQ
This FAQ collects the questions Psychiatric Mental Health Nurse Practitioners (PMHNPs) actually ask about intake forms: APRN state-specific scope of practice, when a collaborative practice agreement is required, how the Ryan Haight Act and the 2023 DEA telehealth rule govern controlled-substance prescribing, CMS E&M billing for psychiatric NP visits, the seven elements of psychotropic informed consent, suicide risk assessment using C-SSRS, drug-drug interaction documentation, and electronic prescribing of controlled substances. Each answer is self-contained and citation-backed. If you need a workflow that captures APRN scope-aware intake and controlled-substance disclosure in one place, Formfy is the AI form builder PMHNPs use; see /guides/how-to-create-psychiatric-np-intake-psychiatric-nurse-practitioners for the step-by-step build guide.
Statistics referenced: APRN scope of practice categorization is maintained by the American Association of Nurse Practitioners (Full, Reduced, Restricted). The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 appears at 21 U.S.C. 829(e). The DEA Diversion Control Division administers the Controlled Substances Act and publishes telehealth rule updates in the Federal Register. CMS E&M coding guidelines were revised effective January 2021 and updated in 2023. The American Psychiatric Association Practice Guideline framework governs informed consent. The federal ESIGN Act and UETA (adopted in 49 states) govern e-signature enforceability.
Frequently Asked Questions
Psychiatric NP intake FAQ
What is APRN scope of practice and why is it state-specific?
Advanced Practice Registered Nurse (APRN) scope of practice is governed by each state Nurse Practice Act and Board of Nursing rules. The American Association of Nurse Practitioners categorizes states into three buckets: Full Practice authority (independent practice in all activities including assessment, diagnosis, prescribing), Reduced Practice (collaborative practice agreement required for at least one element), and Restricted Practice (delegation, supervision, or team management required). The categorization changes periodically as state legislatures adopt or modify Nurse Practice Acts. PMHNPs must accurately disclose their state license, the level of practice authority, and any scope limits in the intake form. Verifying the current state rule before each new state of practice is best practice.
When is a collaborative practice agreement required?
A collaborative practice agreement (sometimes called a supervisory agreement, collaborating physician agreement, or written practice protocol) is required in Reduced Practice and Restricted Practice states for at least one element of APRN practice. Required elements vary by state: prescriptive authority (commonly required), chart review (sometimes required), routine collaboration with a collaborating physician (sometimes required). Some states require the agreement to be filed with the Board of Nursing or Board of Medicine. Even in Full Practice states, some institutions and payors require a collaborative agreement as a condition of credentialing. The intake form should disclose the agreement when required and identify the collaborating physician.
How does the Ryan Haight Act apply to controlled-substance telehealth?
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (21 U.S.C. 829(e)) generally requires an in-person medical evaluation before a controlled substance can be prescribed via telehealth, with limited exceptions. During the COVID-19 public health emergency, the DEA waived this in-person requirement, allowing controlled-substance prescribing via telehealth. The DEA published a final rule in 2023 governing the post-PHE framework, followed by additional rulemaking and extensions through 2024 and 2025. The current framework continues a temporary flexibility for certain controlled-substance prescribing via telehealth without an in-person visit, with requirements that vary by schedule. Practitioners should reference the current DEA rule.
What did the 2023 DEA telehealth rule change?
The DEA published proposed rules in February 2023 that would have ended most COVID-era telehealth flexibilities for controlled-substance prescribing without an in-person visit. After significant public comment, the DEA issued temporary extensions to maintain telehealth flexibility, then a follow-up rulemaking process in 2024 and 2025. As of mid-2025, certain practitioner-patient relationships established via telehealth can continue receiving controlled-substance prescriptions, including buprenorphine for opioid use disorder under specific conditions. The patient intake form should reference the current DEA rule and disclose the practitioner protocol for compliance. Programs should monitor DEA Federal Register notices for updates as the framework continues to evolve.
How do I bill CMS E&M for psychiatric NP visits?
PMHNPs typically bill Centers for Medicare and Medicaid Services (CMS) using Evaluation and Management (E&M) codes (99202 to 99205 for new patients, 99212 to 99215 for established patients) and psychotherapy add-on codes (90833, 90836, 90838) when psychotherapy is integrated. The 2021 CMS E&M coding guidelines revision (effective January 2021) and the 2023 update revised documentation requirements: level selection is based on Medical Decision Making complexity or total time, not History and Physical Exam scoring. Time-based billing requires documentation of total time on the date of encounter. Some states mandate Good Faith Estimate disclosures under the No Surprises Act for self-pay or out-of-network engagements.
What are the elements of psychotropic medication informed consent?
Most state malpractice case law and the American Psychiatric Association Practice Guideline framework require disclosure of seven elements. First, the diagnosis and the rationale for medication. Second, the proposed medication name (generic and brand), dose range, and titration approach. Third, the expected benefits and the time course (most psychotropics take two to six weeks for full effect). Fourth, common side effects (over 5 percent incidence in clinical trials). Fifth, serious side effects, including FDA black-box warnings where applicable. Sixth, alternatives including no treatment. Seventh, the discontinuation plan. The intake form should capture standardized acknowledgment of each element and document the conversation in the chart.
What FDA black-box warnings should the form disclose?
Psychotropic medications with FDA black-box warnings that are commonly prescribed in psychiatric NP practice include: SSRIs and SNRIs (suicidality in patients under 25 on antidepressants), atypical antipsychotics in elderly patients with dementia (increased mortality risk), clozapine (agranulocytosis, myocarditis, seizures, orthostatic hypotension), benzodiazepines (concurrent opioid use, dependence, respiratory depression), stimulants (potential for misuse and dependence), and bupropion (seizure risk). The intake form should disclose the relevant black-box warnings for the specific medication being prescribed and capture patient acknowledgment. Reference the current FDA prescribing information; black-box warnings are periodically updated.
How should the intake form handle suicide risk assessment?
Suicide risk assessment is required at every psychiatric intake. The Columbia Suicide Severity Rating Scale (C-SSRS) is the most widely used standardized tool, referenced by the National Institute of Mental Health and the SAMHSA Suicide Prevention Resource Center. The intake form should incorporate C-SSRS or a comparable validated tool, capture historical suicide attempts and recent ideation, identify means access (firearm, medication stockpile, lethal means restriction conversation), and include a written safety plan template aligned with the Stanley-Brown Safety Planning Intervention. Document any 988 Suicide and Crisis Lifeline education provided. State-specific involuntary commitment processes should also be referenced where relevant.
How do I document drug-drug interactions?
Drug-drug interaction documentation is critical because patients commonly take medications from multiple specialties. The intake form should capture a complete medication reconciliation including prescription medications, over-the-counter medications, herbal supplements, cannabinoid use (medical and recreational cannabis), illicit drug use, and alcohol use. Specific interactions to screen for include MAOI-tyramine interactions, serotonin syndrome risk, QT-prolongation cumulative risk, CYP450 inducer or inhibitor effects on antidepressant and antipsychotic metabolism, and benzodiazepine-opioid concurrent use (FDA black-box warning). Connect the practitioner to the state Prescription Drug Monitoring Program. Document the interaction screen at intake and at every dose change.
What is a Controlled Substance Agreement and is it required?
A Controlled Substance Agreement (sometimes called a Pain Management Agreement or Treatment Agreement) is a written agreement between the prescriber and patient regarding the appropriate use of controlled substances. It is not federally required for psychiatric prescribing but is widely used as a clinical and legal best practice for Schedule II stimulants and benzodiazepines. The agreement typically includes: single-pharmacy commitment, single-prescriber commitment, no early refills except documented loss with police report, no Schedule II after hours, periodic urine drug screening, and consequences for violation. Some state Boards of Nursing recommend or require Controlled Substance Agreements for APRN prescribers of certain schedules.
Do I need EPCS for controlled-substance e-prescribing?
Yes, for federal compliance. Electronic Prescribing of Controlled Substances (EPCS) is required for nearly all Medicare Part D controlled-substance prescriptions and many state laws now also require EPCS for state Medicaid and commercial controlled-substance prescribing. EPCS systems require two-factor authentication for the prescription transmission and DEA-approved technology. EPCS is separate from the patient intake e-signature workflow: the patient consent and intake forms can be e-signed under ESIGN; the actual controlled-substance prescription transmission requires DEA-approved EPCS. Practitioners should verify their EHR or e-prescribing platform is DEA-approved for EPCS before prescribing controlled substances.
How do I handle telehealth across state lines?
The practitioner must be licensed in the state where the patient is physically located during the telehealth session. Some states participate in compacts or interstate agreements that streamline cross-state APRN licensure, including the APRN Compact (which has reached the threshold for implementation but is still in regulatory development as of 2025). The Nurse Licensure Compact (NLC) covers RN-level licensure for member states but does not by itself confer APRN-level practice authority. PMHNPs serving patients in multiple states should hold or apply for licensure in each patient state. The intake form should capture the patient state and confirm practitioner licensure.
What about prior authorization for psychiatric medications?
Many psychiatric medications require commercial or Medicaid prior authorization before pharmacy fill. Atypical antipsychotics, certain stimulants, brand-name drugs when generic equivalents exist, and certain off-label uses commonly require prior auth. The intake form should disclose that prior authorization is a possibility, capture the patient pharmacy information, and obtain consent for the practice to communicate with the payor and pharmacy benefit manager. Document the patient understanding that medication initiation may be delayed while prior auth processes complete (commonly 24 to 72 hours, sometimes longer). State-specific prior auth standards under the No Surprises Act and various state laws may apply.
How long should psychiatric records be retained?
Retention is state-specific. The federal HIPAA baseline is six years from creation or last use. State Boards of Nursing and Boards of Medicine impose retention rules that vary from five to ten years from last contact for adult records. Pediatric records typically require retention until the patient reaches age 21, 25, or 27 depending on state. Some states have longer retention for psychiatric records than for general medical records. The intake form should disclose the practice retention period and the basis (state statute citation) for it. Programs that participate in CMS audits should retain records consistent with CMS retention rules (commonly seven years).
Are e-signed psychiatric intake forms enforceable?
Yes. The federal ESIGN Act and UETA (adopted in 49 states) make e-signed intake and informed consent forms legally equivalent to wet-ink signatures for nearly all psychiatric uses. The DEA generally requires a separate Electronic Prescribing of Controlled Substances (EPCS) workflow for the actual controlled-substance prescription transmission, but the patient intake and informed consent can be e-signed under ESIGN. Tools that capture a tamper-evident audit trail with timestamps, IP addresses, and consent to electronic records produce the strongest record. Formfy, EHR-integrated platforms (SimplePractice, TheraNest, TherapyNotes, Valant), and dedicated e-signature tools all meet this evidentiary bar.
How does the No Surprises Act apply to psychiatric NP visits?
The federal No Surprises Act (effective January 2022) requires healthcare providers to deliver a Good Faith Estimate (GFE) to self-pay and uninsured patients before scheduled services. The GFE must list expected charges for the primary service and any reasonably foreseeable items. Insured patients receiving in-network services are generally not entitled to a GFE under the federal rule, but state laws may extend GFE rights. The intake form should disclose the GFE policy, capture self-pay status, and document GFE delivery. The federal rule has a $400 dispute resolution threshold: if actual charges exceed the GFE by $400 or more, the patient can initiate a payment dispute.
How does Formfy specifically help with psychiatric NP intake forms?
Formfy lets a Psychiatric Mental Health Nurse Practitioner describe the state, the practice authority level, and the medication scope in plain English to the AI form builder, which returns a delivery-ready intake packet with the APRN scope disclosure, collaborative practice agreement reference (when required), controlled-substance prescribing protocol, telehealth consent referencing the current DEA rule, psychotropic informed consent with FDA black-box warnings, C-SSRS-aligned suicide risk fields, drug-drug interaction medication reconciliation, and the e-signature block in a single workflow. Submission-based pricing at $19 to $199 per month covers panel volumes without per-envelope penalties. Audit trails meet ESIGN Act evidentiary requirements. The free 15-day trial requires no credit card.
Related resources
Build a psychiatric NP intake packet in 45 seconds
Free 15-day Formfy trial. No credit card. Submission-based pricing.
Start your free trialLast verified: 2026-04-25. This page is informational; it is not legal or clinical advice. Practitioners should review state APRN scope rules, the current DEA telehealth controlled-substance rule, and CMS E&M coding guidance with counsel and qualified coders.